In last two decades, the lipid nanocarriers have been extensively investigated for their drug
targeting efficiency towards the critical areas of the human body like CNS, cardiac region …

By virtue of their small size, nanomaterials can cross the blood-brain barrier and, when
modified to target specific cells or regions, can achieve high bioavailability at the intended …

By incorporating appropriate drug (s) into lipid (biobased) nanocarriers, one obtains a
combination therapeutic for dementia treatment that targets certain cell-surface scavenger …

Past published studies have already documented that, subsequent to the intravenous
injection of colloidal lipid nanocarriers, apolipoprotein (apo) AI is adsorbed from the blood …

Owing to the complexity of neurodegenerative diseases, multiple cellular types need to be
targeted simultaneously in order for a given therapy to demonstrate any major effectiveness …

Cerebrovascular atherosclerosis, and several other cardiovascular (or" inflamm-aging" type)
diseases, are more frequent and advanced in subjects with Alzheimer's disease compared …

Over the past decades, a frequent co-morbidity of cerebrovascular pathology and
Alzheimer's disease has been observed. Numerous published studies indicate that the …

Sonoporation is a rapidly developing novel technique serving for drug delivery and non-viral
gene therapy. It is based on the interaction between microbubbles located in the …

The cardiovascular risk factors for dementia trigger widespread inflammation and oxidative
stress. These two interacting processes lead to neurodegeneration, gradual …

The pathogenesis of Alzheimer's disease (AD) is not fully understood which limits the
availability of safer and more efficient therapeutic strategies for the management of AD …